The purpose of this study is to evaluate whether or not adding lumateparone to current antidepressant treatment in adults with major depressive disorder experiencing blunted emotion will reduce or eliminate the blunted emotion as rated by the Oxford Depression Questionnaire.
Adults with Major Depressive Disorder who report blunted emotion that is evidenced by responses on the Oxford Depression Questionnaire will add lumateparone to their current treatment once daily for 8 weeks. Primary endpoint will be change fom baseline to week 8 on the Oxford Depression Questionnaire (ODQ). Secondary endpoints will be change from baseline to week 8 on CGI-I and CGI-S as well as change from baseline to week 8 on quality of life as measured by Q-LES-Q-SF.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
lumateparone 42 mg once daily added to current antidepressant treatment
Lumateparone
Future Options Research
State College, Pennsylvania, United States
Change from baseline to week 8 in Oxford Depression Questionnaire score
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.